Cardiome provides U.S. regulatory update for BRINAVESS
Cardiome Pharma announced it has received a response from the FDA regarding the regulatory path for BRINAVESS® (vernakalant hydrochloride, IV). The FDA advised Cardiome the data package proposed by Cardiome would not be sufficient to support a resubmission of the BRINAVESS® NDA. August 21, 2017